Tuesday, May 11, 2021
Home Latest Pharma-News

Latest Pharma-News

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA for the treatment of individuals living with sickle cell disease

Nov 15, 2019: FDA approved Novartis's Adakveo (crizanlizumab-tmca) for the treatment to...

BMS and Pfizer to start a new randamized controlled trial accessing the impact of atrial fibrillation screening on health outcomes in older individuals

Nov 16, 2019: PRINCETON, N.J. and Bristol-Myers Squibb-Pfizer Alliance announced the initiation of a new randomized controlled trial (GUARD-AF) for undiagnosed...

FDA approves Talicia To Treat bacterial infection Linked To Stomach Cancer

Nov 16, 2019: Bacterial infection affects millions of American adults in a year and is one of the strongest known causes of...

Zydus Cadila gets tentative approval from USFDA for Apremilast tablets for the treatment of psoriatic arthritis

Nov 16, 2019: USFDA approved Zydus Cadila’s Apremilast tablets for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis. The US...

New antibacterial drug approved by FDA to treat complicated urinary tract infections for antimicrobial resistance

Nov 14, 2019: The U.S. Food and Drug Administration (FDA)  approved Shionogi’s Fetroja (cefiderocol), an antibacterial drug used for the...

Most Read

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

May 6, 2021: Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the...

Imfinzi, tremelimumab combo boosts survival in lung cancer

May 07, 2021: "POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in...

Vectura and Inspira Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

May 06, 2021: "Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies...

Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants

April 26, 2021: The MELODY Phase III trial for nirsevimab met its primary endpoint of a statistically significant reduction in the incidence...